go back

Rhode Island rates for HCPCS C9081

Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Facilitymedian $446,684 · 10th–90th $446,684–$467,7350%50%90th$446,684Professionalmedian $457,088 · 10th–90th $457,088–$457,0880%50%100%$457,088$500.0K

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample — interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
BCBS
Facility/Professional
Facility
Modifier
Typical Low / Median / Typical High
$446,683.59 / $446,683.59 / $467,735.14
BCBS
Facility/Professional
Professional
Modifier
Typical Low / Median / Typical High
$457,088.19 / $457,088.19 / $457,088.19